Skip to main content

Myocardial Infarction clinical trials at UCSF
2 in progress, 1 open to new patients

  • INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure

    open to eligible people ages 18 years and up

    INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.

    San Francisco, California and other locations

  • Vest Prevention of Early Sudden Death Trial and VEST Registry

    Sorry, in progress, not accepting new patients

    This study explores the hypothesis that wearable defibrillators can impact mortality by reducing sudden death during the first three months after a heart attack in persons with high risk for life-threatening arrhythmias.

    San Francisco, California and other locations

Last updated: